Home/Filings/4/0000899243-23-012021
4//SEC Filing

CLEM BRIAN 4

Accession 0000899243-23-012021

CIK 0001564406other

Filed

May 1, 8:00 PM ET

Accepted

May 2, 7:48 PM ET

Size

21.6 KB

Accession

0000899243-23-012021

Insider Transaction Report

Form 4
Period: 2023-05-02
CLEM BRIAN
President, Clinical Operations
Transactions
  • Disposition to Issuer

    Common stock, $0.001 par value

    2023-05-02$39.00/sh569,826$22,223,2140 total
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2023-05-02$18.00/sh198,140$3,566,5200 total
    Exercise: $21.00Exp: 2030-08-05Common stock, $0.001 par value (198,140 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2023-05-0227,8840 total
    Exercise: $59.63Exp: 2031-02-22Common stock, $0.001 par value (27,884 underlying)
  • Disposition to Issuer

    Performance Stock Option (Right to Buy)

    2023-05-02$23.25/sh281,329$6,540,8990 total
    Exercise: $15.75Exp: 2032-02-21Common stock, $0.001 par value (281,329 underlying)
  • Award

    Performance Stock Option (Right to Buy)

    2023-05-02+73,00073,000 total
    Exercise: $21.96Exp: 2032-10-12Common stock, $0.001 par value (73,000 underlying)
  • Disposition to Issuer

    Performance Stock Option (Right to Buy)

    2023-05-02$17.04/sh73,000$1,243,9200 total
    Exercise: $21.96Exp: 2032-10-12Common stock, $0.001 par value (73,000 underlying)
Footnotes (10)
  • [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation ("CVS Health"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price").
  • [F10]Pursuant to the Merger Agreement, the PSOs were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock underlying such PSOs as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such PSOs.
  • [F2]The shares of the Issuer's common stock reported as disposed by the Reporting Person include restricted stock awards which were, at the Effective Time, automatically assumed by Parent and converted into a corresponding CVS Health restricted stock award, as provided under the Merger Agreement.
  • [F3]The shares of the Issuer's common stock reported as disposed by the Reporting Person include: (a) vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time, (b) unvested RSUs of the Issuer granted on or after February 7, 2023 which were, at the Effective Time, automatically assumed by Parent and converted into a corresponding CVS Health RSU award, subject to the terms and conditions (including applicable vesting provisions) as provided under the Merger Agreement, and
  • [F4](Continued from Footnote 3) (c) unvested RSUs of the Issuer granted before February 7, 2023 which were, at the Effective Time, automatically cancelled and converted into the contractual right to receive a an amount in cash (without interest and subject to applicable withholdings) equal to the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time, subject to the same terms and conditions (including applicable vesting provisions) as applied to such RSUs immediately prior to the Effective Time, except as provided under the Merger Agreement.
  • [F5]Pursuant to the Merger Agreement, at the Effective Time, (a) the vested portion of this option was automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock subject to such option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such vested portion of the option and
  • [F6](Continued from Footnote 5) (b) the unvested portion of this option was automatically cancelled and converted into the contractual right to receive a payment in cash (without interest and subject to applicable tax withholding) equal to the number of shares of the Issuer's common stock subject to such unvested portion of the option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such option, subject to the same terms and conditions (including applicable vesting provisions) as applied to such option immediately prior to the Effective Time, except as provided under the Merger Agreement.
  • [F7]Pursuant to the Merger Agreement, this option was, at the Effective Time, automatically cancelled for no consideration.
  • [F8]The performance-based stock options ("PSOs") previously issued to the Reporting Person automatically vested at the maximum level of performance achievement in connection with the Merger (which constituted a Change of Control, as defined in the PSO award agreement). Pursuant to the Merger Agreement, the PSOs were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock underlying such PSOs as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such PSOs.
  • [F9]Represents performance-based stock options ("PSOs") previously issued to the Reporting Person which automatically vested at the maximum level of performance achievement in connection with the Merger (which constituted a Change of Control, as defined in the PSO award agreement).

Issuer

Oak Street Health, Inc.

CIK 0001564406

Entity typeother

Related Parties

1
  • filerCIK 0001819292

Filing Metadata

Form type
4
Filed
May 1, 8:00 PM ET
Accepted
May 2, 7:48 PM ET
Size
21.6 KB